Rifalazil (KRM-1648, ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the beta-subunit in RNA polymerase[1]. Rifalazil (KRM-1648, ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 µg/ml[3]. Rifalazil (KRM-1648, ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB)[2].
Molekulargewicht:
941.07
Reinheit:
99.64
CAS Nummer:
[129791-92-0]
Formel:
C51H64N4O13
Target-Kategorie:
Antibiotic,Bacterial,DNA/RNA Synthesis
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten